Авторы
Мочкин Н.Е., Мельниченко В.Я., Демина Е.А., Протопопова Ю.В.
ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова», Москва
Аннотация
Риск развития лимфомы Ходжкина (ЛХ) у ВИЧ-инфицированных пациентов в 5–26 раз выше по сравнению с общей популяции. У пациентов с ВИЧ ЛХ может развиваться даже при умеренном снижении иммунитета, несмотря на прием антиретровирусной терапии. В статье рассматривается современная тактика лечения ЛХ у ВИЧ-инфицированных пациентов, а также описывается первый успешный опыт проведения высокодозной химиотерапии с аутологичной трансплантацией гемопоэтических стволовых клеток (ВДХТ+аутоТГСК) у ВИЧ-инфицированного пациента в клинике гематологии ФГБУ «НМХЦ им Н. И. Пирогова». Наше клиническое наблюдение подтверждает эффективность и безопасность ВДХТ+аутоТГСК при лечении рецидивов и рефрактерных форму ЛХ у пациентов с ВИЧ-инфекцией.
Ключевые слова: ВИЧ-инфекция, лимфома Ходжкина, аутологичная трансплантация гемопоэтических стволовых клеток.
Список литературы
1. Gopal S, Achenbach CJ, Yanik EL, Dittmer DP, Eron JJ, Engels EA. Moving Forward in HIV-Associated Cancer. JCO. 2014; 32(9): 876-880. doi: 10.1200/JCO.2013.53.1376.
2. Berhan A, Bayleyegn B, Getaneh Z. HIV/AIDS Associated Lymphoma: Review. BLCTT. 2022; 12: 31-45. doi: 10.2147/BLCTT.S361320.
3. Castro KG, Ward JW, Slutsker L, et al. 1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults. Published online 1993.
4. Navarro JT, Moltó J, Tapia G, Ribera JM. Hodgkin Lymphoma in People Living with HIV. Cancers. 2021; 13(17): 4366. doi: 10.3390/cancers13174366.
5. Bachanova V, Connors JM. Hodgkin lymphoma in the elderly, pregnant, and HIV-infected. Seminars in Hematology. 2016; 53(3): 203-208. doi: 10.1053/j.seminhematol.2016.05.002.
6. Castillo JJ, Bower M, Brühlmann J, et al. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi-institutional retrospective study. Cancer. 2015; 121(3): 423-431. doi: 10.1002/cncr.29066.
7. Carbone A, Gloghini A, Caruso A, De Paoli P, Dolcetti R. The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis. International Journal of Cancer. 2017; 140(6): 1233-1245. doi: 10.1002/ijc.30473.
8. Miller CL, Burkhardt AL, Lee JH, et al. Integral membrane protein 2 of Epstein—barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity. 1995; 2(2): 155-166. doi: 10.1016/S1074-7613(95)80040-9.
9. Caldwell RG, Wilson JB, Anderson SJ, Longnecker R. Epstein-Barr Virus LMP2A Drives B Cell Development and Survival in the Absence of Normal B Cell Receptor Signals. Immunity. 1998; 9(3): 405-411. doi: 10.1016/S1074-7613(00)80623-8.
10. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and Its Ligands in Tolerance and Immunity. Annu Rev Immunol. 2008; 26(1): 677-704. doi: 10.1146/annurev.immunol.26.021607.090331.
11. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7): 1720-1748. doi: 10.1038/s41375-022-01620-2.
12. Jacobson CA, Abramson JS. HIV-Associated Hodgkin’s Lymphoma: Prognosis and Therapy in the Era of cART. Advances in Hematology. 2012; 2012: 1-8. doi: 10.1155/2012/507257.
13. Ruiz M, Parsons C, Cole J. Characterization of HIV-Associated Hodgkin’s Lymphoma in HIV-Infected Patients: A Single-Center Experience. Journal of the International Association of Physicians in AIDS Care. 2012; 11(4): 234-238. doi: 10.1177/1545109711431492.
14. Olszewski AJ, Castillo JJ. Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy. AIDS. 2016; 30(5): 787-796. doi: 10.1097/QAD.0000000000000986.
15. Hentrich M, Müller M, Wyen C, et al. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: Long-term results of a prospective, multicenter study. HemaSphere. 2024; 8(7): e68. doi: 10.1002/hem3.68.
16. Souza AT de, Andrade FR de, Sarmento AC, Villarim CC, Araújo-Filho I, Medeiros KS de. Clinical features in Hodgkin lymphoma patients living with human immunodeficiency virus: A meta-analysis in the antiretroviral therapy era. Int J STD AIDS. Published online June 21, 2024: 09564624241259512. doi: 10.1177/09564624241259512.
17. Chekalov A, Popova M, Tsygankov I, et al. P1077: HODGKIN LYMPHOMA IN PATIENTS WITH HIV: NATIONAL RETROSPECTIVE MULTICENTER STUDY. HemaSphere. 2022; 6: 67-968. doi: 10.1097/01.HS9.0000847176.96022.91.
18. Berenguer J, Miralles P, Ribera JM, et al. Characteristics and Outcome of AIDS-Related Hodgkin Lymphoma Before and After the Introduction of Highly Active Antiretroviral Therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2008; 47(4). [URL].
19. Montoto S, Shaw K, Okosun J, et al. HIV Status Does Not Influence Outcome in Patients With Classical Hodgkin Lymphoma Treated With Chemotherapy Using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the Highly Active Antiretroviral Therapy Era. JCO. 2012; 30(33): 4111-4116. doi: 10.1200/JCO.2011.41.4193.
20. Besson C, Lancar R, Prevot S, et al. High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort. Clinical Infectious Diseases. 2015; 61(9): 1469-1475. doi: 10.1093/cid/civ627.
21. Sorigué M, García O, Tapia G, et al. HIV-infection has no prognostic impact on advanced-stage Hodgkin lymphoma. AIDS. 2017; 31(10): 1445-1449. doi: 10.1097/QAD.0000000000001487.
22. Lawal IO, Ankrah AO, Popoola GO, et al. 18F-FDG-PET metabolic metrics and International Prognostic Score for risk assessment in HIV-infected patients with Hodgkin lymphoma. Nuclear Medicine Communications. 2018; 39(11): 1005-1012. doi: 10.1097/MNM.0000000000000905.
23. Danilov AV, Li H, Press OW, et al. Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leukemia & Lymphoma. 2017; 58(2): 461-465. doi: 10.1080/10428194.2016.1201573.
24. Blanca X, Josep-María R, Pilar M, et al. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin’s lymphoma. haematol. 2007; 92(2): 191-198. doi: 10.3324/haematol.10479.
25. Hartmann P, Rehwald U, Salzberger B, et al. BEACOPP therapeutic regimen for patients with Hodgkin’s disease and HIV infection. Annals of Oncology. 2003;14(10):1562-1569. doi:10.1093/annonc/mdg408.
26. Hentrich M, Berger M, Wyen C, et al. Stage-Adapted Treatment of HIV-Associated Hodgkin Lymphoma: Results of a Prospective Multicenter Study. JCO. 2012; 30(33): 4117-4123. doi: 10.1200/JCO.2012.41.8137.
27. Rubinstein PG, Moore PC, Bimali M, et al. Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial. The Lancet Haematology. 2023; 10(8): e624-e632. doi: 10.1016/S2352-3026(23)00157-6.
28. Mponda M, Kudowa E, Craven DM, et al. Safety, efficacy, and affordability of ABVD for Hodgkin lymphoma in Malawi: a prospective cohort study. eClinicalMedicine. 2024; 69: 102480. doi: 10.1016/j.eclinm.2024.102480.
29. Ansell SM, Bröckelmann PJ, von Keudell G, et al. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from pivotal phase 2 CheckMate 205 study. Blood Advances. Published online August 2, 2023:bloodadvances.2023010334. doi: 10.1182/bloodadvances.2023010334.
30. Armand P, Zinzani PL, Lee HJ, et al. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma. Blood. 2023; 142(10): 878-886. doi: 10.1182/blood.2022019386.
31. Mei MG, Lee HJ, Palmer JM, et al. Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. Blood. 2022; 139(25): 3605-3616. doi: 10.1182/blood.2022015423.
32. Pier LZ, Simonetta V, Antonella A, et al. Brentuximab vedotin in relapsed/refractory Hodgkin’s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. haematol. 2013; 98(8): 1232-1236. doi: 10.3324/haematol.2012.083048.
33. Lurain K, Zarif TE, Ramaswami R, et al. Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States. Clinical Lymphoma, Myeloma and Leukemia. 2024; 24(8): 523-530. doi: 10.1016/j.clml.2024.03.011.
34. Moskowitz AJ, Yahalom J, Kewalramani T, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. 2010; 116(23): 4934-4937. doi: 10.1182/blood-2010-05-282756.
35. Krishnan A, Molina A, Zaia J, et al. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood. 2005; 105(2): 874-878. doi: 10.1182/blood-2004-04-1532.
36. Re A, Michieli M, Casari S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood. 2009; 114(7): 1306-1313. doi: 10.1182/blood-2009-02-202762.
37. National Comprehensive Cancer Network. Cancer in People with HIV (Version: 2.2024). April 4, 2024. [URL].
38. Bae S, Kim YJ, Kim M ju, et al. Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study. J Immunother Cancer. 2021;.9(9):.e002960. doi:.10.1136/jitc-2021-002960.
